This document is an excerpt from the EUR-Lex website
Document 02004D0558-20210101
Commission Decision of 15 July 2004 implementing Council Directive 64/432/EEC as regards additional guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the eradication programmes presented by certain Member States (notified under document number C(2004) 2104) (Text with EEA relevance) (2004/558/EC)Text with EEA relevance
Consolidated text: Commission Decision of 15 July 2004 implementing Council Directive 64/432/EEC as regards additional guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the eradication programmes presented by certain Member States (notified under document number C(2004) 2104) (Text with EEA relevance) (2004/558/EC)Text with EEA relevance
Commission Decision of 15 July 2004 implementing Council Directive 64/432/EEC as regards additional guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the eradication programmes presented by certain Member States (notified under document number C(2004) 2104) (Text with EEA relevance) (2004/558/EC)Text with EEA relevance
No longer in force
)
02004D0558 — EN — 01.01.2021 — 015.001
This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document
COMMISSION DECISION of 15 July 2004 implementing Council Directive 64/432/EEC as regards additional guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the eradication programmes presented by certain Member States (notified under document number C(2004) 2104) (Text with EEA relevance) (OJ L 249 23.7.2004, p. 20) |
Amended by:
|
|
Official Journal |
||
No |
page |
date |
||
L 219 |
37 |
24.8.2007 |
||
M2 |
L 76 |
56 |
19.3.2008 |
|
L 205 |
7 |
6.8.2010 |
||
M4 |
L 268 |
17 |
13.10.2011 |
|
M5 |
L 46 |
10 |
18.2.2014 |
|
M6 |
L 294 |
43 |
10.10.2014 |
|
M7 |
COMMISSION IMPLEMENTING DECISION (EU) 2015/250 of 13 February 2015 |
L 41 |
43 |
17.2.2015 |
M8 |
COMMISSION IMPLEMENTING DECISION (EU) 2015/1765 of 30 September 2015 |
L 257 |
44 |
2.10.2015 |
COMMISSION IMPLEMENTING DECISION (EU) 2015/2278 of 4 December 2015 |
L 322 |
55 |
8.12.2015 |
|
M10 |
COMMISSION IMPLEMENTING DECISION (EU) 2016/1101 of 5 July 2016 |
L 182 |
51 |
7.7.2016 |
M11 |
COMMISSION IMPLEMENTING DECISION (EU) 2017/486 of 17 March 2017 |
L 75 |
27 |
21.3.2017 |
M12 |
COMMISSION IMPLEMENTING DECISION (EU) 2017/888 of 22 May 2017 |
L 135 |
27 |
24.5.2017 |
M13 |
COMMISSION IMPLEMENTING DECISION (EU) 2019/55 of 10 January 2019 |
L 10 |
74 |
14.1.2019 |
COMMISSION IMPLEMENTING DECISION (EU) 2020/1663 of 6 November 2020 |
L 374 |
8 |
10.11.2020 |
|
COMMISSION IMPLEMENTING DECISION (EU) 2020/2109 of 16 December 2020 |
L 427 |
4 |
17.12.2020 |
COMMISSION DECISION
of 15 July 2004
implementing Council Directive 64/432/EEC as regards additional guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the eradication programmes presented by certain Member States
(notified under document number C(2004) 2104)
(Text with EEA relevance)
(2004/558/EC)
Article 1
The programmes presented by the Member States listed in the first column of the table in Annex I for the control and eradication of the infection with the bovine herpesvirus type 1 (BHV1), hereinafter referred to as ‘infectious bovine rhinotracheitis’ or ‘IBR’, in regions of these Member States specified in the second column of the table in Annex I are approved.
Article 2
Bovine animals for breeding and production coming from Member States or regions thereof other than those listed in Annex II and destined for Member States or regions thereof listed in Annex I, shall meet at least the following additional guarantees:
they must come from a holding on which, according to official information, no clinical or pathological evidence of infectious bovine rhinotracheitis has been recorded for the past 12 months;
they must have been isolated in a facility approved by the competent authority for 30 days immediately prior to movement and all bovine animals in the same isolation facility must have remained free of clinical signs of infectious bovine rhinotracheitis during that period;
they and all other bovine animals in the same isolation facility must have been subjected with negative results to a serological test carried out on blood samples, taken not earlier than 21 days after their arrival at the isolation facility, for the detection of the following antibodies:
in the case of vaccinated bovine animals, antibodies against the gE-glycoprotein of the BHV1; or
in the case of unvaccinated bovine animals, antibodies against the entire BHV1.
By way of derogation to paragraph 1, the competent authorities of the Member State of origin may authorise the dispatch to holdings situated in regions listed in Annex I of bovine animals complying with at least one of the following alternative conditions:
the animals originate in a Member State listed in Annex I and come from BHV1-free holdings meeting at least the requirements set down in Annex III;
the animals are intended for meat production and comply with the following conditions:
the animals either
they are transported without coming into contact with animals of lesser health status to a holding of unknown BHV1 status in the Member State of destination listed in Annex I, where according to the approved national eradication programme all animals are fattened indoors, and from which they can only be transported to the slaughterhouse;
the animals originate from holdings on which all bovine animals on the holding older than 15 months of age have been vaccinated and regularly revaccinated and all animals on the holding older than nine months have been subjected with negative result to a serological test for antibodies against the gE-glycoprotein of the BHV1 at intervals of not more than 12 months and the animals have been tested with negative results for antibodies as referred to in paragraph 1(c)(i) on blood samples taken during the past 14 days prior to dispatch;
the animals originate from BHV1-free holdings as defined in Annex III which are situated in a Member State in which infectious bovine rhinotracheitis is a compulsorily notifiable disease and in which within an area of 5 km radius around the holdings there was no clinical or pathological evidence of BHV1-infection during the past 30 days and the animals have been tested with negative results for antibodies as referred to in paragraph 1(c) on a sample of blood taken during the past 14 days prior to dispatch.
Article 3
Bovine animals for breeding and production coming from Member States or regions thereof other than those listed in Annex II and destined for Member States or regions thereof free of infectious bovine rhinotracheitis and listed in Annex II, shall meet the following additional guarantees:
they shall comply with the additional guarantees provided for in Article 2(1)(a) and (b);
they and all other bovine animals in the same isolation facility referred to in Article 2(1)(b) must have been subjected with negative results to a serological test carried out on blood samples taken not earlier than 21 days after their arrival at the isolation facility, for the detection of antibodies against the entire BHV1;
they must not have been vaccinated against infectious bovine rhinotracheitis.
By way of derogation to paragraph 1(a) and (b), the competent authority in the Member State of destination may authorise the introduction of bovine animals intended for meat production onto a BHV1-free holding as defined in Annex III (BHV1-free holding) situated in a region of that Member State listed in Annex II under the following conditions:
the animals must not have been vaccinated against BHV1 and must originate in and have remained since birth on BHV1-free holdings;
the animals are transported without coming into contact with animals of lesser health status;
for at least 30 days immediately prior to dispatch, or since birth where the animals are less than 30 days old, the animals have remained on the holding of origin, or in an isolation facility approved by the competent authority, which is situated in a Member State in which infectious bovine rhinotracheitis is a compulsorily notifiable disease and in which within an area of 5 km radius around the holding or isolation facility there was no clinical or pathological evidence of BHV1 infection during the past 30 days;
the animals have been subjected with negative result either to a serological test for antibodies against the gE-glycoprotein of the BHV1 in the case the animals originate from a BHV1 vaccinated herd, or in all other cases to a serological test for antibodies against the entire BHV1 carried out on a sample of blood taken within 7 days prior to dispatch from the holding referred to in point (c);
on the BHV1-free holding of destination all animals are fattened indoors and are only removed to be transported to the slaughterhouse;
the animals referred to in point (d) are subjected to a serological test for antibodies against the gE-glycoprotein of the BHV1 or the entire BHV1 carried out on a sample of blood taken within 21 to 28 days after arrival in the holding referred to in point (e):
either with negative result in each case; or
the BHV1-free status of the holding remains suspended until the infected animals have been slaughtered within less than 45 days after arrival on the holding, and
Article 4
Bovine animals for breeding and production originating in a Member State or region thereof listed in Annex II and destined for a Member State or region thereof listed in Annexes I or II shall comply with the conditions provided for in Article 2(1)(a).
Article 5
Member States shall ensure that the serological test referred to in Article 2(1)(c)(ii) and in Article 3(1)(b) for the detection of antibodies against the entire BHV1 is standardised against the strong positive, weak positive and negative serum adopted as OIE international standards for BHV1 tests.
Article 6
Decision 2004/215/EC is repealed.
Article 7
This Decision shall apply from 26 July 2004.
Article 8
This Decision is addressed to the Member States.
ANNEX I
Member States |
Regions of Member States to which the additional guarantees for infectious bovine rhinotracheitis apply in accordance with Article 9 of Directive 64/432/EEC |
Belgium |
All regions |
France |
Région Auvergne et Rhône-Alpes Région Bourgogne-Franche-Comté Région Bretagne Région Centre-Val de Loire Région Grande Est Région Hauts-de-France Région Ile-de-France Région Normandie Région Nouvelle-Aquitaine Région Occitanie Région Pays de la Loire Région Provence-Alpes-Côte d'Azur |
Italy |
Region Friuli-Venezia Giulia Autonomous Province of Trento |
Luxembourg |
All regions |
ANNEX II
Member States |
Regions of Member States to which the additional guarantees for infectious bovine rhinotracheitis apply in accordance with Article 10 of Directive 64/432/EEC |
Czechia |
All regions |
Denmark |
All regions |
Germany |
All regions |
Italy |
Region Valle d'Aosta Autonomous Province of Bolzano |
Austria |
All regions |
Finland |
All regions |
Sweden |
All regions |
▼M15 ————— |
ANNEX III
BHV1-free holding
1. |
A holding keeping bovine animals shall be considered free of BHV1 infection if it complies with the conditions set out in this Annex.
|
2. |
The BHV1-free status of a holding keeping bovine animals shall be retained if:
2.1.
the conditions in points 1.1 to 1.4 continue to apply, and
2.2.
at least one of the following control regimes is applied on the holding within a 12-month period:
2.2.1.
a serological investigation for antibodies against BHV1 has been carried out with negative results in each case on at least one individual sample of blood taken from all bovine animals older than 24 months of age;
2.2.2.
a serological investigation for antibodies against BHV1 has been carried out with negative results in each case on at least:
—
one individual sample of milk taken from all lactating female bovine animals, either individually or in a pool of milk samples taken from not more than five animals; and
—
one individual sample of blood taken from all non-lactating female bovine animals older than 24 months of age, and from all male bovine animals older than 24 months of age;
2.2.3.
in the case of dairy farms on which at least 30 % of the bovine animals are lactating female bovine animals, a serological investigation for antibodies against BHV1 has been carried out with negative results in each case on at least:
—
two milk samples collected with an interval of three to 12 months from a bulk of milk of not more than 50 lactating female bovine animals, depending on the specification of the test employed; and
—
one individual sample of blood, taken from all non-lactating female bovine animals older than 24 months of age, and from all male bovine animals older than 24 months of age.
|
3. |
The BHV1-free status of a holding keeping bovine animals shall be suspended where during the investigations referred to in points 2.2.1 to 2.2.3. an animal has reacted with positive results in a test for antibodies against BHV1. |
4. |
The BHV1-free status of a holding which was suspended in accordance with point 3, shall only be restored after a serological investigation for antibodies against BHV1, commencing not earlier than 30 days after the removal of the seropositive animals, has been carried out with negative result in each case on at least:
—
two samples of milk taken with an interval of at least two months from all lactating female bovine animals, either individually or in a pool of milk samples taken from not more than five animals; and
—
two samples of blood, taken with an interval of at least three months from all non-lactating female bovine animals, and from all male bovine animals.
|
Note:
(a) Where reference is made in this Annex to a serological test for the detection of antibodies against BHV1, the principles laid down in Article 2(1)(c) relating to the vaccination status of the tested animals shall apply.
(b) The size of the pool of milk samples referred to in this Annex, may be modulated based on documented evidence that the test is under all circumstances of day to day laboratory work sensitive enough to detect a single weak positive reaction in the pool of the modulated size.